Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully understood. Besides the most c
Taken together, dexrazoxane is unlikely to increase secondary malignancy risk. Beta-blockers, ACE inhibitors, or ARBs Beta-blockers, ACE inhibitors, and ARBs were evaluated in randomized controlled trials for primary prevention of anthracycline-induced cardiotoxicity (Table 3). LVEF dropped ...
Saleh, Y., Abdelkarim, O., Herzallah, K.et al.Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.
anthracycline‐induced cardiotoxicitycancerchemotherapyclinical practice guidelinescongestive heart failurepharmacogenomic screeningPURPOSECardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer...
In this retrospective observational study, we aimed to investigate the potential of natural language processing (NLP) for drug repositioning by analyzing the preventive effects of cardioprotective drugs against anthracycline-induced cardiotoxicity (AIC) using electronic medical records. We evaluated the effect...
anthracycline cardiotoxicity children heart failure systematic review Introduction Anthracycline-induced clinical heart failure (A-CHF), clinical cardiotoxicity, has been acknowledged since the introduction of anthracyclines [1]. Despite this adverse effect, anthracyclines form an important part of the treatment...
and in themetabolism and transport of anthracyclines. These data willhave to be verified in further clinical trials before any at-tempts of their application in the individual cardiotoxicityprediction can be undertaken. In the meantime, anthracy-cline-induced cardiotoxicity can be best reduced byapplic...
Anthracyclines (i.e., doxorubicin, daunorubicin) have significant impact on outcome in many pediatric chemotherapy protocols and therefore remain the mainstay of treatment. The objective of this study was to identify the risk factors for anthracycline induced cardiac dysfunction in pediatric patients. Mu...
Carvedilol is promising for preventing anthracycline-induced cardiotoxicity (AIC). This review appraised the preventive effects of carvedilol against AIC based on randomized controlled trials (RCTs). The Cochrane Collaboration Central Register of Controlled Trials, PubMed, and Embase databases were searched...
LVEF ≤ 30% was selected as the cutoff because these patients are at significant risk for CHF (Batist et al., 2001). The blinded review was conducted by a second cardiologist at Yale University noted for his expertise in doxorubicin-induced cardiotoxicity. All MUGA scan data were interpreted ...